Companies

HATO Medical Technologies empowers healthcare professionals to make prompt decisions, accurate triage, correct referrals, and save lives and valuable resources by getting it right the first time. The company utilises artificial intelligence to enhance the accuracy and efficiency of electrocardiogram (ECG) interpretation. By providing innovative solutions, HATO aims to support healthcare professionals, especially those without specialised cardiology expertise, in diagnosing and treating cardiovascular diseases more effectively.  

Cardiolyse provides a chronic and post-discharge cardiovascular disease patient monitoring platform with medical-grade AI heart health analytics (CE class 2a, 19 arrhythmias) that enables remote vital sign monitoring and personalized patient reports for early diagnostics and better care.  

CorFlux aims to be the world’s leading analyzing software for estimating the risk of aortic aneurysm rupture. The current clinical method does not take into account other influencing elements than the aortic diameter in the risk evaluation. However, a high number of aortic ruptures appear before the diameter reaches the limit for surgery. CorFlux decision-making support allows physicians to identify high-risk aneurysm patients more easily, leading to life savings.  

Efficient lowering of blood cholesterol is pivotal in reducing the risk for heart attack and stroke, the most frequent causes of death globally. Different cholesterol-lowering drugs are available, but it is difficult to find an optimal treatment strategy for each person, resulting in suboptimal treatment and an increased risk for heart attack and stroke for many patients. The Moncyte analysis tool sheds light on why individuals respond differently to cholesterol-lowering medication. This will enable novel personalized treatment strategies, helping more patients to achieve their blood cholesterol target levels and reducing cardiovascular morbidity and mortality.  

Sonai Health develops a new solution for heart diagnosis, utilising patented sensor solution, cloud service and machine learning.  

Cardiomtec is a Finnish 2020 founded corporation holding more than 20 years of experience of developing medical devices. Cardiomtec specializes in developing applications and portable devices for wellbeing technology. Cardiomtec products are affordable, small and reliable. With Cardiomtec devices one can measure and evaluate cardiac function of an individual at home environment, data is uploaded to a cloud server from where a medical doctor can review it with web-portal.

EpiHeart is a young medical device company focused on enabling Cardiac Micrograft Therapy™, an adjuvant therapy administered during cardiac interventions such as coronary artery bypass grafting surgery. Cardiac Micrograft Therapy™ is a novel therapy for treating ischemic injury and consequent ischemic scars and heart failures. The company is focused on the development and commercialization of medical device packages to enable the therapy and it aims to drive the therapy into mainstream clinical use. The first-in-man clinical trial has already been completed in academic setting. The company is a spin-out from the University of Helsinki and the HUS Helsinki University Hospital.